eversyn GmbH is a biotechnology company and Max Planck spin-off based in Magdeburg, Germany. We develop cell-free, enzyme-based manufacturing technologies that make high-value glycans—complex carbohydrates important in nutrition and biopharma—more accessible at both research and industrial scale. Our platform combines engineered multi-enzyme cascades, activated/nucleotide sugars, and specialized enzymes to enable the efficient production of complex oligosaccharides and precise in-vitro glycoengineering of proteins. Key application areas include human milk oligosaccharides, glycan building blocks, and tailored glycosylation for therapeutic proteins such as antibodies, vaccines, recombinant proteins, and viral vectors. By overcoming the cost, scalability, and flexibility limitations of conventional cell-based production, eversyn helps partners develop next-generation nutritional ingredients and biopharmaceuticals with more controllable glycan structures.
I am a Principal Scientist at eversyn GmbH, a Max Planck spin-off in Magdeburg, Germany, working at the intersection of glycoengineering, biocatalysis, and scalable cell-free manufacturing. My focus is on converting advanced carbohydrate science into practical technologies for nutrition, biopharma, and next-generation therapeutic development.
At eversyn, I contribute expertise in enzymatic synthesis, multi-enzyme cascades, activated/nucleotide sugars, human milk oligosaccharides (HMOs), and tailored biomolecule glycosylation. Our cell-free approach uses the precision of enzymes to make high-value glycan building blocks, glycoengineering tools, and custom glycans more accessible from R&D through industrial scale.
Seeking for non-German partners to complete consortium: An integrated platform for AI-guided enzyme discovery, high-throughput cell-free screening, and advanced glycoanalytics the sustainable production of glycosylated products.